IBT receives a further SEK 35 million funding from BioGaia

September 7, 2015

To support Infant Bacterial Therapeutics efforts to develop a drug to prevent the fatal disease necrotizing enterocolitis, BioGaia’s board of directors has resolved to invest a further SEK 35 million in IBT.

Read the official IBT press release here
Read the official BioGaia press release here

Latest press releases

2024-09-01 19:27 IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.

2024-08-30 18:38 IBT's phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality Regulatory MAR

2024-08-28 08:30 Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024 Regulatory

2024-08-15 16:44 Patent for Infant Bacterial Therapeutics has been approved in the USA Regulatory MAR

2024-07-08 16:40 “The Connection Study” is completed Regulatory MAR

News

Latest press releases